164 related articles for article (PubMed ID: 38254824)
1. CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture.
Harfmann M; Schröder T; Głów D; Jung M; Uhde A; Kröger N; Horn S; Riecken K; Fehse B; Ayuk FA
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254824
[TBL] [Abstract][Full Text] [Related]
2. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
4. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy.
Wellhausen N; O'Connell RP; Lesch S; Engel NW; Rennels AK; Gonzales D; Herbst F; Young RM; Garcia KC; Weiner D; June CH; Gill SI
Sci Transl Med; 2023 Sep; 15(714):eadi1145. PubMed ID: 37651540
[TBL] [Abstract][Full Text] [Related]
5. CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
Liao C; Wang Y; Huang Y; Duan Y; Liang Y; Chen J; Jiang J; Shang K; Zhou C; Gu Y; Liu N; Zeng X; Gao X; Tang Y; Sun J
Adv Sci (Weinh); 2023 Sep; 10(27):e2207394. PubMed ID: 37485647
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
8. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Haematologica; 2022 Feb; 107(2):437-445. PubMed ID: 33375774
[TBL] [Abstract][Full Text] [Related]
9. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells.
Roex G; Campillo-Davo D; Flumens D; Shaw PAG; Krekelbergh L; De Reu H; Berneman ZN; Lion E; Anguille S
J Transl Med; 2022 Mar; 20(1):124. PubMed ID: 35287669
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
11. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
12. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
[TBL] [Abstract][Full Text] [Related]
13. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
[TBL] [Abstract][Full Text] [Related]
14. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
Hasan MF; Campbell AR; Croom-Perez TJ; Oyer JL; Dieffenthaller TA; Robles-Carrillo LD; Cash CA; Eloriaga JE; Kumar S; Andersen BW; Naeimi Kararoudi M; Tullius BP; Lee DA; Copik AJ
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38081778
[TBL] [Abstract][Full Text] [Related]
15. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
16. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
17. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
[TBL] [Abstract][Full Text] [Related]
18. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression.
Fousek K; Watanabe J; Joseph SK; George A; An X; Byrd TT; Morris JS; Luong A; Martínez-Paniagua MA; Sanber K; Navai SA; Gad AZ; Salsman VS; Mathew PR; Kim HN; Wagner DL; Brunetti L; Jang A; Baker ML; Varadarajan N; Hegde M; Kim YM; Heisterkamp N; Abdel-Azim H; Ahmed N
Leukemia; 2021 Jan; 35(1):75-89. PubMed ID: 32205861
[TBL] [Abstract][Full Text] [Related]
20. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]